Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$43.31+0.42 (+0.98%)
Close on Nov 13, 2026Market cap $124.47MP/E –Yield –
Spruce Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Spruce Biosciences's total debt was $7.82M at Sep 30, 2026. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $4.92M in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $1.75M | -47.7% |
| FY2023 | Dec 31, 2023 | $3.34M | -32.1% |
| FY2022 | Dec 31, 2022 | $4.92M | +0.8% |
| FY2021 | Dec 31, 2021 | $4.88M | +9.0% |
| FY2020 | Dec 31, 2020 | $4.48M | +0.7% |
| FY2019 | Dec 31, 2019 | $4.45M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.82M | +1351.2% |
| Q2 FY2026 | Jun 30, 2026 | $7.09M | +652.0% |
| Q1 FY2026 | Mar 31, 2026 | $6.46M | +380.6% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $539.00K | -74.9% |
| Q2 FY2025 | Jun 30, 2025 | $943.00K | -62.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.35M | -54.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.75M | -47.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.15M | -42.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.55M | -38.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.94M | -34.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.34M | -32.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.74M | -23.8% |
| Q2 FY2023 | Jun 30, 2023 | $4.13M | -15.5% |
| Q1 FY2023 | Mar 31, 2023 | $4.52M | -7.5% |
| Q4 FY2022 | Dec 31, 2022 | $4.92M | +0.8% |
| Q3 FY2022 | Sep 30, 2022 | $4.90M | +0.7% |
| Q2 FY2022 | Jun 30, 2022 | $4.89M | +0.7% |
| Q1 FY2022 | Mar 31, 2022 | $4.89M | +1.0% |
| Q4 FY2021 | Dec 31, 2021 | $4.88M | +9.0% |
| Q3 FY2021 | Sep 30, 2021 | $4.87M | +8.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.86M | +9.2% |
| Q1 FY2021 | Mar 31, 2021 | $4.84M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.48M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.47M | – |
| Q4 FY2019 | Dec 31, 2019 | $4.45M | – |
See a number that looks wrong?